61 results about "Clinical screening" patented technology

The invention discloses an esophageal adenocarcinoma plasma circulation microbial marker combination, a reagent, a kit, a risk prediction model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The esophageal adenocarcinoma plasma circulating microbial marker combination disclosed by the invention comprises enterobacteriaceae, cilia, prevotella, ackermania, lactobacillus fermentum and streptococcus. When the esophageal adenocarcinoma plasma circulating microbial marker combination is used for verifying esophageal adenocarcinoma patients and healthy controls, the AUC is 0.952, the sensitivity is 100%, the specificity is 80.00%, the accuracy is 91.43%, the positive predictive value is 86.96%, and the negative predictive value is 100%; the esophageal adenocarcinoma plasma circulating microbial marker combination can effectively distinguish esophageal adenocarcinoma patients from healthy people, is suitable for early screening of esophageal adenocarcinoma, and has remarkable clinical screening application value.

A method for preparing a dual-mode immune structure based on a surface-enhanced Raman substrate and an up-conversion luminescent probe, and an application thereof. The dual-mode immune structure based on a surface-enhanced Raman substrate and an up-conversion luminescent probe comprises a copper / black phosphorus / silver nanoflower composite immunosubstrate and a NaGdF4:Yb3+ / Er3+ up-conversion nanoparticle immunoprobe, wherein the copper / black phosphorus / silver nanoflower composite immunosubstrate is prepared using an electrochemical reduction method, and the NaGdF4:Yb3+ / Er3+ up-conversion nanoparticle immunoprobe is prepared using a hydrothermal method. During the application to cancer detection, assembling an immunosubstrate and an immunoprobe realizes the combination of up-conversion luminescence and surface-enhanced Raman spectroscopy technology for realizing dual-mode detection of cancer biomarkers. Thus, simple operation and high detection sensitivity are achieved, thereby facilitating efficient and precise clinical screening and identification of cancer biomarkers.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for simultaneously detecting APOE2 / 3 / 4 protein and application of the monoclonal antibody combination. The combination comprises a monoclonal antibody 3H7 and a monoclonal antibody 2C8, can simultaneously recognize three protein isomers APOE2 / 3 / 4 with high specificity and high sensitivity, and is suitable for rapid detection reagent development. The monoclonal antibody 3H7 and the monoclonal antibody 2C8 respectively have clearly defined complementary determining region sequences, and CDR amino acid sequences of heavy chain variable regions and light chain variable regions of the monoclonal antibody 3H7 and the monoclonal antibody 2C8 are respectively SEQ ID NO.1-6 and SEQ ID NO.7-12. A colloidal gold immunochromatography test strip rapid detection tool is constructed, the detection sensitivity can reach 0.5 ng / mL, extremely high specificity is achieved, and an efficient and reliable solution is provided for clinical screening and disease risk assessment of APOE protein.

The application discloses a kind of multi-modal medical image segmentation method, device, computer equipment and storage medium, comprising: obtaining the multi-modal medical image of the same examinee and pre-processing and spatial registration;The target segmentation concept is standardized and analyzed to generate prompt;Using basic segmentation model obtains multiple candidate segmentation results of each modality;Constitute credibility gating model, assess the credibility score of each candidate result and carry out screening, obtain the credible instance of each modality;Establish the corresponding relationship between cross-modal credible instance to form instance group;Each instance group is executed evidence weighted fusion and conflict resolution, and the final segmentation result of each target is obtained;Output multi-instance segmentation result and corresponding instance-level uncertainty index.The application can effectively reduce the false detection and result fluctuation of basic model in multi-modal image, improve the consistency and reliability of cross-modal segmentation, and provide robust segmentation result for clinical screening.

This invention discloses a lncRNA biomarker associated with AML, characterized in that the lncRNA biomarker is lncRNA FOXN3-AS1, and the nucleotide sequence of lncRNA FOXN3-AS1 is shown in SEQ ID NO: 1. This invention also discloses the application of a detection kit and method in the diagnosis and prognosis of AML. The lncRNA FOXN3-AS1 of this invention, as an auxiliary diagnostic biomarker for clinical detection of AML, has the advantages of simple operation, low cost, and accurate detection, making it suitable for clinical screening. The biomarker provided by this invention can be applied to the preparation of early AML assessment products, which is beneficial for further elucidating the pathogenesis of AML and helps in the discovery of novel small molecule drug targets with potential therapeutic value.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.

This invention discloses a multi-task behavioral-EEG synchronous monitoring method for schizophrenia screening, relating to the field of schizophrenia screening. The method includes: designing a multi-task temporal loading paradigm based on clinical screening needs; simultaneously collecting EEG signals and behavioral data of subjects during the execution of the multi-task temporal loading paradigm, and preprocessing the collected raw data; extracting multidimensional features from the preprocessed data, wherein the multidimensional features include EEG feature groups, behavioral feature groups, and time-varying feature groups; constructing a multimodal fusion discriminant model, inputting the multidimensional features into the multimodal fusion discriminant model, and outputting a baseline risk probability and a schizophrenia risk index. The advantages of this invention are: achieving efficient, accurate, and objective screening of the core cognitive dimensions of schizophrenia, effectively improving the sensitivity and specificity of screening.

The application belongs to the technical field of biology, and specifically discloses a truncated mutant of ANKRD11 and application thereof. The ANKRD11 gene mutant is any one of the following: a nucleic acid, wherein the nucleic acid has a target fragment, and the target fragment is compared with a wild-type ANKRD11 gene with a sequence of SEQ ID NO. 1, nucleotides from No. 1910 to No. 1913 are deleted; a polypeptide, wherein the polypeptide has a p.K637Tfs*15 mutation compared with a protein encoded by a wild-type ANKRD11 gene with a sequence of SEQ ID NO. 2. The application also relates to application of a reagent for detecting the aforementioned ANKRD11 gene mutant in screening of a KBG syndrome risk population. In the present disclosure, the pathogenic gene spectrum of the KBG syndrome is widened, the understanding of the disease is strengthened, experience is provided for clinical screening and diagnosis of the disease, and a basis is provided for prenatal diagnosis.

The invention discloses application of sEVs membrane protein detection in breast cancer drug resistance early warning products, and belongs to the field of biomedicine. A plurality of breast cancer drug resistance associated sEVs membrane proteins are selected to form the combined marker, so that the detection accuracy can be effectively improved. By applying the antibody, the primer and the probe designed by the invention and combining the design of four-layer cascade amplification and multi-target conjoint analysis, four-round signal amplification can be completed, the limitation of a traditional single-target detection method is effectively broken through, the detection sensitivity is remarkably improved, the detection time is shortened, the detection cost is reduced, and the possibility is provided for clinical large-scale screening.

The invention relates to the technical field of biomedical detection, in particular to a multi-dimensional tumor marker joint detection device and a using method thereof.The device comprises a sample processing module, a sequencing module, a marker extraction module, a feature fusion and detection module and a result output module, and 6 types of markers such as chromosome copy variation, microsatellite instability and the like are extracted respectively. The method comprises the following steps: collecting a body fluid sample to extract cfDNA, directly constructing a library without special treatment, obtaining effective data through whole genome sequencing, synchronously extracting six types of markers through each module of the device, optimizing an algorithm to adapt to low-depth data, inputting an integrated learning model to output a risk score, and finally outputting related information by a result output module. The method does not need special experimental treatment, realizes low-cost and high-accuracy joint detection, and meets the clinical large-scale screening requirements.

Disclosed herein are improved methods of expanding cell populations and methods of producing organoids from pluripotent stem cells, as well as compositions and uses thereof, compositions comprising liquid components that can be used to carry out these methods for supplementing amino acids, and kits comprising components for carrying out these methods and / or products of using these methods. These methods can be carried out without the need for xenogeneic and ambiguous basement membrane matrices for cell culture, which enables the achievement of good production specification (GMP) compliant methods for producing organoids for various uses such as clinical screening and treatment, methods for treating liver-related diseases or conditions and methods for screening candidate compounds or compositions for treating liver-related diseases or conditions are included.

The present application discloses a FabI enzyme inhibitor and use thereof. The FabI enzyme inhibitor is a compound as represented by Formula I, provides a new option for clinical screening and / or preparation of drugs for the treatment of diseases associated with FabI enzyme activity.

The invention belongs to the technical field of artificial intelligence, and discloses a multi-modal depression recognition method based on personalized embedding. The method comprises the following steps: modeling an audio time sequence, a visual time sequence and interaction thereof, supporting personalized feature injection, carrying out coding and self-attention fusion on audio and visual time sequence features through deep learning, and realizing depression recognition in combination with personalized embedding. Personality feature description generated by a large language model is introduced, personalized embedding is obtained through semantic coding, the model is injected in the fusion stage, and self-adaptive adjustment of depression characterization differences of different personality types is achieved; according to the double-branch collaborative back translation classification mechanism, the recognition capability of the model on diversified depression characterization is remarkably improved through personalized mask and label back translation, and particularly, high precision and generalization capability are still kept under the scene of data imbalance or high sample heterogeneity. The method can be widely applied to intelligent mental health monitoring, human-computer interaction, clinical screening and other scenes, and has good cross-group adaptability and actual deployment potential.

The invention discloses an internal arteriovenous fistula portable intelligent auscultation instrument for hemodialysis, and relates to the technical field of medical equipment. An alarm, three auscultation result indicating lamps with different colors, an equipment switch and an electric quantity indicating lamp are arranged on the auscultation instrument main machine, an equipment power supply, a control module, a wireless data transmission module and an AI noise recognition chip are arranged in the auscultation instrument main machine, and an auscultation head and a conduction tube are arranged on the outer side of the auscultation instrument main machine. And an auxiliary fixing mechanism is arranged on the stethoscope head. A noise reduction acoustic filter screen is arranged in the auscultation head to accurately filter interference, a signal amplification module at the tail end of a conduction tube amplifies weak blood flow sound, an AI noise recognition chip with a clinical noise spectrum pre-recorded is matched, the internal fistula noise state can be automatically recognized without depending on professional auscultation experience, visual feedback is achieved through a three-color auscultation result indicator lamp, linkage early warning is matched with an alarm, and the internal fistula noise state can be automatically recognized. Common medical care can quickly complete clinical screening, and a patient can also perform self-examination at home, so that the risks of missed judgment and misjudgment are thoroughly avoided.

The invention discloses a gastrointestinal tumor early screening and auxiliary diagnosis interaction system, belongs to the technical field of gastrointestinal tumor auxiliary diagnosis, and solves the technical problem of low accuracy of an existing artificial intelligence screening method. The system comprises: a risk prediction model module, which takes a structured test index of a patient as an input, and adopts an integrated learning and stacking generalization strategy to output a risk probability that the patient suffers from gastrointestinal tumors; the clinical dialogue interaction module is used for providing a doctor-patient question and answer interface and allowing doctors to interact with the clinical dialogue interaction module in a dialogue mode so as to obtain auxiliary diagnosis suggestions, disease interpretation and health propaganda and education content given by the clinical dialogue interaction module according to the risk probability; and the standardized patient simulation evaluation module is used for constructing a simulated'standardized patient 'case according to historical medical records and evaluating the performance of the risk prediction model module and the clinical dialogue interaction module in the simulated clinical situation, and the system can greatly improve the clinical screening efficiency and the diagnosis accuracy.

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.

The invention discloses a preparation method of a skin pricking liquid for allergy detection in a safflower injection preparation, and provides an efficient screening method of allergens in the safflower injection preparation and a preparation method of an allergen skin pricking liquid in order to solve the problems that chemical components in the safflower injection preparation are complex, sensitization components are not clear and the like. According to the method, chemical components in the safflower injection preparation are rapidly clarified by adopting a high performance liquid chromatography-mass spectrometry technology; carrying out molecular docking on the identified chemical components, human serum albumin, MRGPRX2 protein and RhoA protein by using a molecular docking technology, and screening out compounds combined with the proteins; further performing allergen evaluation and confirmation on the compound screened by the molecular docking technology by using a surface plasmon resonance instrument; according to the SPR technology, it is confirmed that the safflower injection preparation allergen is prepared into skin pricking liquid which is used for clinically screening safflower injection preparation potential allergy people, and the purpose of greatly reducing the allergy occurrence rate is achieved.

The present application relates to the technical field of biological medicine, in particular to a lipid metabolite combination for early diagnosis of VKH and application thereof, by obtaining plasma samples of patients with initial acute stage (early stage) VKH syndrome and healthy controls, and constructing sample-full lipid quantitative expression matrix, screening differential lipids through PCA unsupervised analysis and OPLS-DA supervised model, further screening lipids with high diagnostic performance by using elastic net logistic regression model, finally obtaining a diagnostic marker combination composed of 25 lipid metabolites, solving the technical problems of existing VKH diagnosis technology, such as invasiveness, insufficient sensitivity and stability of protein marker detection, limited diagnostic efficiency, lack of systematicness and standardized process in lipidomics research, achieving the effect of non-invasive, efficient, high sensitivity and high specificity of early auxiliary diagnosis of VKH syndrome, and providing objective and reliable technical means for precise identification of atypical cases and large-scale clinical screening.

This invention belongs to the field of biotechnology, specifically disclosing novel mutations of ANKRD11 and their applications. The ANKRD11 gene mutation can be any of the following: a nucleic acid having a target fragment, wherein the target fragment has a G repeat at position 4708 compared to the wild-type ANKRD11 gene with sequence SEQ ID NO.1; or a polypeptide having the p.E1570Gfs*71 mutation compared to the wild-type protein encoded by the ANKRD11 gene with sequence SEQ ID NO.2. The invention also relates to the application of reagents for detecting the aforementioned ANKRD11 gene mutation in screening individuals at risk for KBG syndrome. This disclosure broadens the pathogenic gene spectrum of KBG syndrome, enhances the understanding of the disease, provides experience for clinical screening and diagnosis of the disease, and also provides a basis for prenatal diagnosis.

The invention belongs to the technical field of gene diagnosis, and discloses an SLC16A2 gene mutant and application of the SLC16A2 gene mutant in AHDS disease risk analysis. The specifically disclosed SLC16A2 gene mutant is any one of nucleic acid, a target fragment exists in the nucleic acid, and compared with a wild type SLC16A2 gene with the sequence of SEQ ID NO.1, the target fragment has c.963964delinsAA mutation, and the target fragment has c.963964delinsAA mutation. Compared with a protein coded by a wild type SLC16A2 gene with a sequence of SEQ ID NO.2, the polypeptide has p.Y321 * mutation. Meanwhile, the invention discloses application of a reagent for detecting the SLC16A2 gene mutant in preparation of a product for screening AHDS. According to the invention, the pathogenic gene spectrum of the AHDS is expanded, the cognition of a clinician on the disease is improved, experience is accumulated for clinical screening and diagnosis of the disease, and a basis is provided for prenatal diagnosis.

This invention discloses a morphological adaptive and feature decoupling network method for medical image segmentation. Addressing the technical challenges of segmenting small medical lesions, this invention achieves high-precision and robust segmentation results through the collaborative design of a morphological adaptive ResNeXt module and a context-details decoupling module. The heterogeneous dual-stream architecture of the context-details decoupling module achieves explicit decoupling of semantic context and high-frequency details. Combined with large-kernel spatial gating and global residual connections, it effectively filters background noise, prevents weak features from being overwhelmed, and significantly improves the detection rate of small lesions. The morphological adaptive ResNeXt module's fully grouped geometric alignment strategy configures dedicated offsets and modulation scalars for each semantic subspace, suppressing deformation drift and allowing the receptive field to adaptively fit the complex, non-rigid boundaries of the lesion, eliminating edge jaggedness and providing reliable computer-aided support for clinical screening of small medical lesions.

The application provides a novel DNA methylation marker TAGMe-5 for tumor identification and use thereof. The tumor marker TAGMe-5 of the application shows significant DNA methylation difference between cancer adjacent tissue and cancer tissue, and the difference has significant statistical significance, and the difference is shown in numerous tumors such as solid tumors and non-solid tumors. The solid tumors include lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, biliary tract tumor, etc. The non-solid tumors include hematological tumors, lymphoma, etc. Therefore, the tumor marker of the application can be used for clinical screening of pan-cancer, molecular diagnosis, prognosis and efficacy evaluation.

The invention discloses a human enterovirus A-D group broad-spectrum detection reagent based on a fluorescent quantitative PCR (Polymerase Chain Reaction) technology. The human enterovirus A-D group broad-spectrum detection reagent comprises a specific upstream primer group, a specific downstream primer group and a specific probe group, by adopting a fluorescent quantitative detection method, not only can the viruses be quickly screened, but also the load of the viruses can be quantified, and the fluorescent quantitative detection method has great advantages for researching the infection state of the viruses and the influence of the viruses on the disease progress. The reagent has the characteristics of high specificity, high sensitivity, high repeatability, high reproducibility, simplicity in operation, low time consumption and the like, and can greatly improve the detection efficiency of the enterovirus and reduce the detection cost when being applied to large-scale clinical screening, and the detection result can provide important reference for formulating an individualized treatment scheme, so that the reagent has a wide application prospect. Therefore, the application has important value and significance for clinical rapid screening and diagnosis and improvement of treatment effect.

This invention discloses an immunomodulator, specifically relating to a class of compounds that inhibit IL-17A and their use as immunomodulators in the preparation of drugs. This invention discloses the use of compounds represented by formula (I), or their stereoisomers, in the preparation of drugs that inhibit IL-17A, providing a new option for clinical screening and / or preparation of drugs for diseases related to IL-17A activity.

The invention relates to an antigen construct for rapid immune detection, in particular to an antigen molecule for realizing dimerization or trimerization through foldon or a variant thereof. The antigen construct can enhance the conformation stability and improve the antibody binding efficiency, so that the sensitivity and shelf life stability in colloidal gold, fluorescent microspheres, ELISA (enzyme-linked immuno sorbent assay) and other in-vitro diagnosis methods in immunochromatography are remarkably improved. The construct is suitable for antibody detection of rabies, influenza, coronavirus, Brucella, tuberculosis and the like in zoonosis and HIV, HBV, HCV, syphilis and the like in human infectious diseases, and can be widely applied to clinical screening, animal quarantine, family self-test and public health emergency monitoring.

The invention relates to the technical field of medical artificial intelligence and disease risk prediction, and discloses a pancreatic cancer risk prediction model optimization method based on metabolic syndrome data, and the method comprises the steps: a training stage: obtaining historical clinical data of five physiological abnormalities of a sample individual, carrying out the grading assignment of the historical clinical data based on a metabolic syndrome diagnosis standard, and carrying out the prediction of a pancreatic cancer risk prediction model; in the application stage, the clinical data of a target individual are subjected to same preprocessing and feature engineering and input into the risk prediction model, and the risk prediction model is obtained by combining a pancreatic cancer diagnosis tag and training a logistic regression model through a maximum likelihood estimation method. And calculating to obtain a pancreatic cancer risk assessment result of the target individual. According to the method, data modeling is carried out by innovatively integrating metabolic syndrome data and diabetes disease course information, accurate and early individualized prediction of the pancreatic cancer risk is realized, and an effective tool is provided for clinical screening and intervention.

The invention discloses a multiplex fluorescent quantitative PCR (Polymerase Chain Reaction) detection reagent for synchronously detecting four DNA (Deoxyribose Nucleic Acid) viruses related to infectious infertility. The detection reagent comprises specific primers and probes aiming at human microviruses, adenoviruses, polyoma viruses and adeno-associated viruses; the multiple fluorescence detection method used in the invention not only can synchronously detect four infectious DNA viruses in a single reaction tube, but also can simultaneously measure the load of the viruses, and has great value for researching infectious clinical diseases. The reagent disclosed by the invention has the characteristics of strong specificity, high sensitivity, good stability, simplicity in operation, less time consumption and the like, and can greatly improve the detection efficiency and reduce the detection cost when the method is used for performing large-scale clinical screening on the infection of the four viruses; meanwhile, the detection result can also provide important reference for formulating an individualized treatment scheme, so that the kit has important clinical application value and social significance for realizing symptomatic medication and improving the treatment effect.

The invention discloses a JAK3 kinase inhibitor compound and application thereof, and particularly discloses a compound shown as a formula IA, or application of a stereoisomer or pharmaceutically acceptable salt of the compound in preparation of JAK3 kinase inhibitor drugs. A new choice is provided for clinical screening and / or preparation of drugs for treating diseases related to the activity of the JAK3 kinase inhibitor.

This invention discloses an interpretable diagnostic model, method, and electronic device for rare craniofacial diseases. The model includes a medical vision-language feature encoding network, a supervised hierarchical contrastive learning module, a KL regularized progressive unfreezing module, and an interpretable diagnostic output module. First, image-text pairs are constructed. By introducing disease semantic priors, an adaptive soft-boundary contrastive learning loss function is built, which tolerates visual overlap while preserving the feature manifold topology of phenotypic similar diseases. Second, KL divergence is used to monitor the drift of feature distribution between layers, and progressive unfreezing of the model is achieved through trust domain constraints. This invention effectively avoids catastrophic forgetting during model fine-tuning, improving the diagnostic accuracy of rare craniofacial diseases while outputting interpretable attention heatmaps and facial feature descriptions that are precisely aligned with pathological features, providing an efficient and reliable technical solution for early clinical screening and assisted diagnosis.

The invention belongs to the technical field of biomedicine detection, and provides a preparation method of a double-ligand peptide / UiO-66-NH2-atAYG fluorescent probe and application of the double-ligand peptide / UiO-66-NH2-atAYG fluorescent probe in CA153 detection.The fluorescent probe has the advantages of being high in sensitivity and specificity, good in stability, low in cost, easy and convenient to operate and the like, can meet the requirement for precise detection of trace CA153, and has a good application prospect. The method is especially suitable for primary medical institutions and large-scale clinical screening.